On the ropes, In­fin­i­ty gets a deal for du­velis­ib, with $0 up front as PI3k floun­ders

So this is where PI3k can­cer drugs have fall­en to.

In­fin­i­ty Phar­ma­ceu­ti­cals, which once tout­ed its lead drug du­velis­ib as a block­buster con­tender, has now …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.